Sk Biopharmaceuticals Morgan Bond
326030 Stock | 103,800 500.00 0.48% |
Sk Biopharmaceutica's financial leverage is the degree to which the firm utilizes its fixed-income securities and uses equity to finance projects. Companies with high leverage are usually considered to be at financial risk. Sk Biopharmaceutica's financial risk is the risk to Sk Biopharmaceutica stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
326030 |
Given the importance of Sk Biopharmaceutica's capital structure, the first step in the capital decision process is for the management of Sk Biopharmaceutica to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Sk Biopharmaceuticals Co to issue bonds at a reasonable cost.
Popular Name | Sk Biopharmaceutica Morgan Stanley 3591 |
Equity ISIN Code | KR7326030004 |
Bond Issue ISIN Code | US61744YAK47 |
S&P Rating | Others |
Maturity Date | 22nd of July 2028 |
Issuance Date | 24th of July 2017 |
Coupon | 3.591 % |
Sk Biopharmaceuticals Outstanding Bond Obligations
Morgan Stanley 3591 | US61744YAK47 | Details |
Understaning Sk Biopharmaceutica Use of Financial Leverage
Sk Biopharmaceutica's financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures Sk Biopharmaceutica's total debt position, including all outstanding debt obligations, and compares it with Sk Biopharmaceutica's equity. Financial leverage can amplify the potential profits to Sk Biopharmaceutica's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if Sk Biopharmaceutica is unable to cover its debt costs.
Please read more on our technical analysis page.
Pair Trading with Sk Biopharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sk Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sk Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.Moving together with 326030 Stock
0.8 | 207940 | Samsung Biologics | PairCorr |
0.62 | 302440 | SK Bioscience | PairCorr |
0.91 | 298380 | ABL Bio | PairCorr |
0.9 | 144510 | Green Cross Lab | PairCorr |
Moving against 326030 Stock
The ability to find closely correlated positions to Sk Biopharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sk Biopharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sk Biopharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sk Biopharmaceuticals Co to buy it.
The correlation of Sk Biopharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sk Biopharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sk Biopharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sk Biopharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in 326030 Stock
Sk Biopharmaceutica financial ratios help investors to determine whether 326030 Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 326030 with respect to the benefits of owning Sk Biopharmaceutica security.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.